Business Context and Reporting Period
This Form 8-K is filed by AntriaBio, Inc. (not Rezolute, Inc.) on February 18, 2015, reporting events occurring between December 4, 2014, and February 23, 2015. The filing details the final closing of a Private Investment in Public Equity (PIPE) financing, the execution of amended employment agreements for key executives, and the adoption of a new stock option plan.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company received gross cash proceeds of $9.2 million from the PIPE Financing (excluding placement agent fees and transaction costs).
- Security Pricing: Units were priced at $1.85 per unit, consisting of one share of common stock and one warrant.
- Warrant Terms: Investor warrants are exercisable at $2.50 per share for 36 months. A placement agent financing warrant covers 17.5% of gross proceeds, exercisable at $2.50 for 7 years.
- Stock Option Plan: The 2015 Non-Qualified Stock Option Plan authorizes the issuance of up to 6,850,000 shares. Initial grants were made with an exercise price of $2.06 per share.
- Compensation Increases: Base salaries were increased for the CEO (to $450,000), CSO (to $350,000), and CAO (to $145,000).
Material Changes and Executive Actions
- Financing Closure: The PIPE Financing was completed in three stages (Initial, Subsequent, and Final Close) with the final close occurring on February 18, 2015.
- Executive Compensation: On February 23, 2015, the Board approved 2014 target bonuses for the CEO and CSO (100% of target) and the CAO (150% of target). Some executives elected to defer payment.
- Equity Grants: Significant stock options were granted to named executive officers and directors, including 1,740,000 options to the CEO and 695,000 to the CSO.
Outlook, Risks, and Contingencies
- Registration Rights: The Company agreed to file a registration statement within 90 days of the PIPE close to allow investors to resell shares. The statement must remain effective until shares are eligible for resale under Rule 144.
- Liquidity and Use of Proceeds: The filing does not explicitly state the specific use of proceeds beyond general financing, though the capital raise is intended to support operations and development.
- Regulatory Status: Securities issued in the PIPE were sold under Section 4(a)(2) and Rule 506 exemptions and are not registered for public resale until the registration statement becomes effective.
Investor Verification Checklist
- Verify the exact number of shares issued in the PIPE Financing to calculate total dilution.
- Confirm the filing date and effectiveness status of the registration statement required within 90 days of the February 18, 2015 close.
- Review the full text of the amended employment agreements (Exhibits 10.2, 10.3, 10.4) for termination provisions and vesting schedules.
- Assess the impact of the 6.85 million share option pool on future dilution potential.
- Check subsequent filings for the actual cash balance post-transaction costs, as the $9.2 million figure is gross proceeds.